Your browser is no longer supported. Please, upgrade your browser.
Settings
ILMN Illumina, Inc. daily Stock Chart
ILMN [NASD]
Illumina, Inc.
IndexS&P 500 P/E53.90 EPS (ttm)5.56 Insider Own0.40% Shs Outstand147.00M Perf Week5.53%
Market Cap44.07B Forward P/E39.90 EPS next Y7.52 Insider Trans-15.40% Shs Float146.44M Perf Month-1.90%
Income826.00M PEG2.50 EPS next Q1.39 Inst Own91.90% Short Float1.79% Perf Quarter-3.65%
Sales3.33B P/S13.23 EPS this Y89.40% Inst Trans0.50% Short Ratio2.43 Perf Half Y-8.54%
Book/sh23.83 P/B12.58 EPS next Y15.15% ROA11.10% Target Price336.47 Perf Year34.38%
Cash/sh23.05 P/C13.00 EPS next 5Y21.52% ROE20.70% 52W Range221.49 - 372.61 Perf YTD-0.04%
Dividend- P/FCF58.45 EPS past 5Y39.20% ROI9.90% 52W High-19.54% Beta1.15
Dividend %- Quick Ratio2.20 Sales past 5Y19.10% Gross Margin69.00% 52W Low35.37% ATR8.10
Employees6200 Current Ratio2.50 Sales Q/Q19.50% Oper. Margin25.70% RSI (14)54.95 Volatility1.84% 2.71%
OptionableYes Debt/Eq0.56 EPS Q/Q21.30% Profit Margin19.40% Rel Volume0.71 Prev Close292.47
ShortableYes LT Debt/Eq0.25 EarningsJan 29 AMC Payout0.00% Avg Volume1.08M Price299.82
Recom1.90 SMA203.35% SMA50-0.53% SMA200-2.72% Volume773,532 Change2.51%
Jan-03-19Upgrade UBS Neutral → Buy
Oct-09-18Initiated UBS Neutral
Aug-07-18Upgrade Morgan Stanley Underweight → Equal-Weight
Jul-31-18Reiterated Canaccord Genuity Buy $330 → $340
Feb-05-18Upgrade Citigroup Neutral → Buy
Jan-31-18Upgrade First Analysis Sec Equal-Weight → Overweight $277
Jan-05-18Initiated BTIG Research Neutral
Jan-05-18Downgrade William Blair Outperform → Mkt Perform
Jan-02-18Upgrade Wells Fargo Market Perform → Outperform
Oct-25-17Upgrade Robert W. Baird Neutral → Outperform $184 → $228
Oct-23-17Upgrade Janney Sell → Neutral
Oct-23-17Upgrade Deutsche Bank Hold → Buy $195 → $250
Sep-26-17Resumed Goldman Neutral $200
Aug-07-17Upgrade Canaccord Genuity Hold → Buy $170 → $215
Aug-02-17Upgrade First Analysis Sec Underweight → Equal-Weight
Apr-26-17Reiterated Cantor Fitzgerald Neutral $155 → $170
Mar-20-17Upgrade Leerink Partners Mkt Perform → Outperform
Feb-01-17Reiterated UBS Buy $180 → $185
Jan-18-17Initiated Deutsche Bank Hold $160
Jan-10-17Upgrade BofA/Merrill Neutral → Buy
Feb-15-19 01:50PM  Final trades: GE, Royal Caribbean, Illumina, Cisco & Invitation Homes CNBC Videos
Feb-14-19 06:01PM  Stanley Druckenmiller's Top 6 Buys for the 4th Quarter GuruFocus.com
Feb-12-19 03:27PM  Illumina Could Rally to Break Its Downtrend TheStreet.com
11:40AM  The Best S&P 500 Stocks of 2018 Investopedia
10:48AM  Illumina Inc (ILMN) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
10:01AM  Pacific Biosciences (PACB) Incurs Q4 Loss, Revenues Fall Y/Y Zacks
Feb-11-19 05:03PM  The 1 Stock I'd Buy Right Now Motley Fool
Feb-10-19 09:00AM  The $100 Billion Investing Opportunity That Could Revolutionize Cancer Treatment Motley Fool
09:00AM  Health Care Is About to Improve Dramatically; Here's How to Play it TheStreet.com
Feb-08-19 08:00AM  Factors of Influence in 2019, Key Indicators and Opportunity within The Estee Lauder Companies, The New York Times, Twenty-First Century Fox, Kemet, Illumina, and Computer Programs and New Research Emphasizes Economic Growth GlobeNewswire
Feb-06-19 08:55AM  Illumina Names Susan E. Siegel to Its Board of Directors Business Wire
Feb-04-19 01:36PM  Final trades ahead of a big batch of earnings CNBC Videos
Feb-03-19 10:09AM  The Week Ahead In Biotech: Conferences, Clinical Trials, Earnings And IPOs Benzinga
09:00AM  5 Things to Expect From Illumina in 2019 Motley Fool
Feb-01-19 01:42PM  Final trades: Chevron, Illumina, Nvidia & KKR CNBC Videos
07:10AM  Illumina, Inc. (NASDAQ:ILMN): Will The Growth Last? Simply Wall St.
Jan-31-19 09:30AM  CBM or ILMN: Which Is the Better Value Stock Right Now? Zacks
07:13AM  Edited Transcript of ILMN earnings conference call or presentation 29-Jan-19 10:00pm GMT Thomson Reuters StreetEvents
Jan-30-19 05:01PM  What Happened in the Stock Market Today Motley Fool
01:45PM  Illumina Sinks on Fourth-Quarter Earnings Miss TheStreet.com
10:58AM  Morgan Stanley: Illumina's Q1 Guidance Puts 2019 Targets In Question Benzinga
09:58AM  Illumina (ILMN) Q4 Earnings Lag Estimates, Revenues Top Mark Zacks
09:07AM  Illumina Stock Drops, Pandora Rises and Three More Wednesday Morning Movers Barrons.com
08:16AM  Why Illumina's Growth Rate Slowed in the Fourth Quarter -- Temporarily Motley Fool
08:12AM  The Daily Biotech Pulse: Roche Scraps Alzheimer's Disease Trials, Amgen Issues Weak Guidance Benzinga
07:23AM  Dow Jones Futures: Apple, AMD Drive Premarket Rally Investor's Business Daily
04:14AM  Illumina (ILMN) Q4 2018 Earnings Conference Call Transcript Motley Fool
Jan-29-19 05:34PM  Illumina: 4Q Earnings Snapshot Associated Press
05:25PM  Illumina Earnings Mixed, But Stryker Stock Pops On Quarterly Beat Investor's Business Daily
04:05PM  Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2018 Business Wire
11:07AM  Illumina Earnings miss, Revenue beats In Q4 Investing.com
09:54AM  Thermo Fisher (TMO) Down on Business Divestment Declaration Zacks
09:54AM  Here's Why You Should Snap Up Abbott (ABT) Stock Right Now Zacks
07:24AM  Illumina's Q4 Earnings Outlook Benzinga
Jan-28-19 10:12AM  Cerner (CERN) to Report Q4 Earnings: What's in the Cards? Zacks
07:29AM  Will Core Business Units Boost McKesson's (MCK) Q3 Earnings? Zacks
Jan-27-19 06:05PM  3 Top Healthcare Growth Stocks to Buy in 2019 Motley Fool
05:15PM  3 Things You Can Expect From Illumina's Q4 Earnings Update Motley Fool
Jan-25-19 02:41PM  5 Innovation-Led Stocks For The Health Care Boom Investopedia
09:49AM  Will Lower Revenues Dampen Juniper's (JNPR) Q4 Earnings? Zacks
08:53AM  AmerisourceBergen (ABC) Q1 Earnings: What's in the Cards? Zacks
08:24AM  Here's Why You Should Buy Tandem Diabetes (TNDM) Stock Now Zacks
08:12AM  What's in Store for Edwards Lifesciences' (EW) Q4 Earnings? Zacks
Jan-24-19 01:49PM  Will Top-Line Growth Support Corning's (GLW) Q4 Earnings? Zacks
11:41AM  Will GPU Product Introduction Benefit AMD's Q4 Earnings? Zacks
11:15AM  Will Flagship Impella Drive ABIOMED's (ABMD) Q3 Earnings? Zacks
10:19AM  What's Setting the Tone for Hologic's (HOLX) Q1 Earnings? Zacks
10:03AM  Can Solid Consumables Drive Illumina's (ILMN) Q4 Earnings? Zacks
06:12AM  Factors Expected to Influence Microsoft's (MSFT) Q2 Earnings Zacks
Jan-23-19 05:05PM  3 Top Healthcare Stocks to Buy in January Motley Fool
03:13PM  Henry Schein Animal Health Spin-Off Approaches, Costs Mount (revised) Zacks
01:19PM  Final Trades: T-Mobile, Illumina, Bristol-Myers. Plus, Ma... CNBC Videos
09:16AM  Can Diagnostic Revenues Fuel PerkinElmer's (PKI) Q4 Earnings? Zacks
09:13AM  Can Overall Growth Fuel Align Technology's (ALGN) Q4 Earnings? Zacks
Jan-22-19 08:13AM  ResMed Launches Nasal Mask Devise, Extends AirFit Portfolio Zacks
Jan-21-19 10:02AM  Quest Diagnostics' Core Diagnostics Strong Amid Several Woes Zacks
07:58AM  Neogen Gains on Strong Genomic Arm Amid Stiff Competition Zacks
Jan-18-19 08:00PM  Five Ways to Profit from the Boom in Life Science Barrons.com
10:00AM  Illumina (ILMN) Is Up 1.45% in One Week: What You Should Know Zacks
08:59AM  Here is Why Growth Investors Should Buy Illumina (ILMN) Now Zacks
08:44AM  Can Medical Devices Strength Drive Abbott (ABT) Q4 Earnings? Zacks
08:06AM  Here's Why You Should Buy Myriad Genetics (MYGN) Stock Now Zacks
Jan-17-19 08:58AM  Henry Schein Animal Health Spin-Off Approaches, Cost Mounts Zacks
Jan-16-19 05:50PM  Illumina (ILMN) Gains But Lags Market: What You Should Know Zacks
12:08PM  REIT Stocks, Medical Stocks Lead New Buys By The Best Mutual Funds Investor's Business Daily
09:58AM  The Zacks Analyst Blog Highlights: Intuitive Surgical, Illumina, HCA, Elanco Animal and Humana Zacks
09:32AM  Why You Should Consider Buying Omnicell (OMCL) Stock Now Zacks
Jan-15-19 04:05PM  Illumina to Announce Fourth Quarter and Fiscal Year 2018 Financial Results on Tuesday, January 29, 2019 Business Wire
07:26AM  5 Great Medical Stocks to Buy Ahead of Q4 Earnings Zacks
06:19AM  QIAGEN QFT-Plus Ok'd in Canada, Test Customer Base Expands Zacks
Jan-14-19 07:07AM  Here's Why You Should Invest in Illumina (ILMN) Stock Now Zacks
Jan-13-19 07:00AM  Here's Why Illumina Gained 37.3% in 2018 Motley Fool
Jan-11-19 09:30AM  Has Illumina (ILMN) Outpaced Other Medical Stocks This Year? Zacks
Jan-10-19 09:15AM  Stocks Stay Positive on Trade Hopes, Still Patient Fed Zacks
Jan-09-19 07:01AM  Illumina sees Q4 revenue above expectations, provides a mixed outlook MarketWatch
Jan-08-19 09:30PM  Why Investors Didn't Like Illumina's J.P. Morgan Presentation -- but Should Have Motley Fool
05:04PM  What Happened in the Stock Market Today Motley Fool
04:28PM  This IBD 50 Medical Giant Is Diving On Its Outlook But 'Don't Panic' Investor's Business Daily
10:10AM  Why Illumina (ILMN) is Poised to Beat Earnings Estimates Again Zacks
08:15AM  The Daily Biotech Pulse: Amgen Slashes Cholesterol Drug Device Prices By 60%, Takeda Completes Shire Purchase Benzinga
Jan-07-19 05:50PM  Illumina (ILMN) Outpaces Stock Market Gains: What You Should Know Zacks
03:53PM  Top 5 Health Care Stocks of 2018 by Performance Investopedia
12:27PM  Heres What Illumina, Inc.s (NASDAQ:ILMN) P/E Is Telling Us Simply Wall St.
06:50AM  Today's Research Reports on Trending Tickers: Exact Sciences and Illumina ACCESSWIRE
Dec-27-18 04:10PM  Why This IBD Stock Of The Day 'Continues To Push For New Highs' Investor's Business Daily
02:45PM  Robots, DNA And Implantable Devices Why 2019 Isn't Your Dad's Medtech Investor's Business Daily
09:15AM  Christmas Comes a Day Late Zacks
Dec-26-18 08:17AM  3 Medical Stocks Likely to Emulate Illumina's Success in 2019 Zacks +7.67%
Dec-24-18 09:28AM  These Growth Stocks Drive This Mutual Fund's Special Outperformance Investor's Business Daily
Dec-21-18 01:36PM  6 Genome Sequencing Stocks to Buy for Big Health-Care Profits Kiplinger
09:15AM  Stocks Still Angry at the Fed; Drop Another 1.5%+ Zacks
Dec-20-18 04:05PM  Illumina to Webcast Upcoming Investor Conference Presentations Business Wire
08:48AM  5 Blue Chip Stocks to Lead Despite Rising Global Shocks Investopedia
Dec-17-18 09:05AM  Here's Why You Should Buy Express Scripts (ESRX) Stock Now Zacks
Dec-14-18 10:25AM  AMAG to Acquire Ciraparantag Maker Perosphere Pharmaceuticals Zacks
06:43AM  Here's Why You Should Hold Allscripts Stock in Your Portfolio Zacks
Dec-13-18 07:32AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Dec-12-18 01:51PM  10 Stocks That Can Move Higher Whatever Happens InvestorPlace
09:30AM  Is Illumina (ILMN) Outperforming Other Medical Stocks This Year? Zacks
08:16AM  BD Gets Enterprise Level Cybersecurity Assessment From UL Zacks
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array. The company also provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and noninvasive prenatal testing, as well as products support services. It serves genomic research centers, academic institutions, government laboratories, and hospitals; and pharmaceutical, biotechnology, agrigenomics, and commercial molecular diagnostic laboratories, as well as consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. It operates in North America, Europe, Latin America, the Asia-Pacific region, the Middle East, and South Africa. The company has a strategic partnership with Loxo Oncology, Inc. to develop and commercialize a multi-gene panel for broad tumor profiling; and strategic collaboration with Bristol-Myers Squibb Company. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FLATLEY JAY TDirectorFeb 13Sale293.663,300969,078344,868Feb 14 04:21 PM
RAGUSA ROBERT PSVP, Global Quality & OpsFeb 12Option Exercise0.004,540015,316Feb 14 04:32 PM
Van Oene MarkSVP Chief Commercial OfficerFeb 12Option Exercise0.005,639015,419Feb 14 04:36 PM
FLATLEY JAY TDirectorFeb 12Option Exercise0.0028,8880358,929Feb 14 04:21 PM
Ronaghi MostafaSVP & CTOFeb 12Option Exercise0.009,782079,217Feb 14 04:34 PM
deSouza Francis APresident and CEOFeb 12Option Exercise0.0024,621082,910Feb 14 04:17 PM
Dadswell CharlesSVP & General CounselFeb 12Option Exercise0.004,127011,064Feb 14 04:15 PM
OSTADAN OMEADSVP Mktg, Prod & Strat PlanFeb 12Option Exercise0.009,492033,875Feb 14 04:23 PM
EPSTEIN ROBERT SDirectorFeb 01Option Exercise51.171,00051,1704,256Feb 05 04:45 PM
Dadswell CharlesSVP & General CounselFeb 01Sale280.1112434,7346,879Feb 05 04:44 PM
deSouza Francis APresident and CEOFeb 01Sale282.953,000848,85464,104Feb 05 04:46 PM
EPSTEIN ROBERT SDirectorFeb 01Sale280.111,000280,1103,256Feb 05 04:45 PM
FLATLEY JAY TDirectorJan 23Sale303.533,3001,001,649329,979Jan 25 04:27 PM
FLATLEY JAY TDirectorJan 09Sale296.203,300977,460333,279Jan 11 04:35 PM
EPSTEIN ROBERT SDirectorJan 02Option Exercise51.171,00051,1704,256Jan 04 05:05 PM
EASTHAM KARINDirectorJan 02Option Exercise71.094,000284,36015,838Jan 04 05:03 PM
EPSTEIN ROBERT SDirectorJan 02Sale294.711,000294,7103,256Jan 04 05:05 PM
EASTHAM KARINDirectorJan 02Sale294.085,0001,470,38110,838Jan 04 05:03 PM
deSouza Francis APresident and CEOJan 02Sale293.333,000879,99467,104Jan 04 05:04 PM
Dadswell CharlesSr VP & General CounselJan 02Sale294.7112436,5447,003Jan 04 05:01 PM
FLATLEY JAY TDirectorDec 26Sale273.873,300903,771336,579Dec 28 05:36 PM
FLATLEY JAY TDirectorDec 12Sale334.133,3001,102,629371,559Dec 13 07:26 PM
OSTADAN OMEADEVP Ops, Products, StrategyDec 10Sale321.50644207,04621,613Dec 12 01:59 PM
Stapley MarcEVP Strategy & Corp DevelopmtDec 06Sale329.691,000329,6956,957Dec 07 05:17 PM
EPSTEIN ROBERT SDirectorDec 03Option Exercise51.171,00051,1706,101Dec 04 09:03 PM
Dadswell CharlesSr VP & General CounselDec 03Sale343.57566194,4615,606Dec 04 09:01 PM
EPSTEIN ROBERT SDirectorDec 03Sale343.571,345462,1024,756Dec 04 09:03 PM
deSouza Francis APresident and CEODec 03Sale345.903,0001,037,68863,643Dec 04 09:02 PM
FLATLEY JAY TDirectorNov 28Sale321.803,3001,061,940373,410Nov 30 04:24 PM
OSTADAN OMEADEVP Ops, Products, StrategyNov 23Sale306.74644197,54122,257Nov 27 04:39 PM
FLATLEY JAY TDirectorNov 14Sale312.503,3001,031,250376,710Nov 16 04:09 PM
Ronaghi MostafaSr VP & CTONov 12Option Exercise37.0410,000370,40079,612Nov 14 05:44 PM
Ronaghi MostafaSr VP & CTONov 12Sale314.6310,0003,146,33769,612Nov 14 05:44 PM
Stapley MarcEVP Strategy & Corp DevelopmtNov 07Sale336.681,000336,6806,957Nov 09 04:23 PM
Van Oene MarkSVP Chief Commercial OfficerNov 05Option Exercise29.446,000176,64017,126Nov 07 05:05 PM
Van Oene MarkSVP Chief Commercial OfficerNov 05Sale326.116,8352,228,95010,291Nov 07 05:05 PM
EPSTEIN ROBERT SDirectorNov 01Option Exercise51.171,00051,1706,447Nov 02 05:01 PM
deSouza Francis APresident and CEONov 01Sale310.852,100652,78870,235Nov 02 05:03 PM
EPSTEIN ROBERT SDirectorNov 01Sale311.861,346419,7645,101Nov 02 05:01 PM
FLATLEY JAY TDirectorOct 24Sale310.583,3001,024,914382,304Oct 26 04:35 PM
Ronaghi MostafaSr VP & CTOOct 10Option Exercise37.0410,000370,40080,805Oct 12 04:37 PM
Ronaghi MostafaSr VP & CTOOct 10Sale311.8410,0003,118,42470,805Oct 12 04:37 PM
FLATLEY JAY TDirectorOct 10Sale321.583,3001,061,214385,604Oct 12 04:35 PM
EPSTEIN ROBERT SDirectorOct 01Option Exercise51.171,00051,1706,793Oct 03 04:17 PM
deSouza Francis APresident and CEOOct 01Sale369.612,100776,18372,335Oct 03 04:20 PM
EPSTEIN ROBERT SDirectorOct 01Sale369.151,346496,8765,447Oct 03 04:17 PM
FLATLEY JAY TDirectorSep 26Sale360.813,3001,190,673388,904Sep 28 05:29 PM
FLATLEY JAY TDirectorSep 12Sale351.663,3001,160,478392,204Sep 14 09:25 PM
Ronaghi MostafaSr VP & CTOSep 10Option Exercise37.0410,000370,40080,805Sep 11 05:49 PM
Ronaghi MostafaSr VP & CTOSep 10Sale347.0710,0003,470,70970,805Sep 11 05:49 PM
EPSTEIN ROBERT SDirectorSep 07Option Exercise51.171,00051,1707,139Sep 11 05:45 PM
EPSTEIN ROBERT SDirectorSep 07Sale345.141,346464,5585,793Sep 11 05:45 PM
Van Oene MarkSVP Chief Commercial OfficerSep 04Sale354.181,091386,41011,126Sep 06 06:09 PM
deSouza Francis APresident and CEOSep 04Sale353.662,100742,68674,435Sep 06 06:26 PM
Stapley MarcEVP Strategy & Corp DevelopmtSep 04Sale352.051,000352,0548,516Sep 06 08:22 PM
Ronaghi MostafaSr VP & CTOAug 10Option Exercise37.0410,000370,40080,805Aug 14 04:07 PM
Ronaghi MostafaSr VP & CTOAug 10Sale331.3910,0003,313,86170,805Aug 14 04:07 PM
Stapley MarcEVP Strategy & Corp DevelopmtAug 02Sale324.801,000324,7987,516Aug 06 08:10 PM
OSTADAN OMEADEVP Ops, Products, StrategyAug 02Sale320.701,334427,81424,484Aug 06 08:11 PM
deSouza Francis APresident and CEOAug 01Sale327.412,100687,55576,535Aug 03 03:03 PM
EPSTEIN ROBERT SDirectorJul 23Sale311.15500155,5756,139Jul 24 07:21 PM
deSouza Francis APresident and CEOJul 12Sale300.003,300990,00078,635Jul 13 02:39 PM
Ronaghi MostafaSr VP & CTOJul 10Option Exercise37.047,500277,80078,496Jul 12 07:39 PM
Ronaghi MostafaSr VP & CTOJul 10Sale288.897,5002,166,70170,996Jul 12 07:39 PM
deSouza Francis APresident and CEOJul 02Sale276.142,100579,88782,271Jul 03 06:20 PM
EPSTEIN ROBERT SDirectorJun 21Sale288.45500144,2256,639Jun 22 07:12 PM
Ronaghi MostafaSr VP & CTOJun 11Option Exercise28.4510,500298,72581,496Jun 13 06:21 PM
Stapley MarcEVP Strategy & Corp DevelopmtJun 11Sale285.181,446412,3648,516Jun 13 06:24 PM
Ronaghi MostafaSr VP & CTOJun 11Sale284.8310,5002,990,75970,996Jun 13 06:21 PM
deSouza Francis APresident and CEOJun 01Sale272.912,100573,10784,371Jun 04 08:54 PM
OSTADAN OMEADEVP Ops, Products, StrategyJun 01Sale274.611,335366,60425,818Jun 04 08:57 PM
EPSTEIN ROBERT SDirectorMay 21Sale271.00500135,5006,588May 22 05:25 PM
EASTHAM KARINDirectorMay 21Sale269.801,000269,80212,288May 22 05:23 PM
Ronaghi MostafaSr VP & CTOMay 16Option Exercise28.4510,000284,50080,996May 18 07:39 PM
Ronaghi MostafaSr VP & CTOMay 16Sale267.7110,0002,677,13570,996May 18 07:39 PM
FLATLEY JAY TDirectorMay 14Sale268.001,460391,2804,000May 16 09:40 PM
deSouza Francis APresident and CEOMay 14Sale268.632,100564,12486,471May 16 09:37 PM
OSTADAN OMEADEVP Ops, Products, StrategyMay 02Sale242.601,314318,77627,153May 04 06:53 PM
BOWMAN A BLAINEDirectorMay 01Option Exercise55.143,000165,42619,868May 03 06:23 PM
BOWMAN A BLAINEDirectorMay 01Sale241.453,000724,33616,868May 03 06:23 PM
Van Oene MarkSVP Chief Commercial OfficerApr 12Sale238.481,400333,87212,217Apr 13 07:30 PM
Dadswell CharlesSr VP & General CounselApr 03Sale230.9111626,7867,875Apr 04 07:32 PM
BOWMAN A BLAINEDirectorApr 02Option Exercise44.513,000133,53019,868Apr 04 07:29 PM
BOWMAN A BLAINEDirectorApr 02Sale230.133,000690,38316,868Apr 04 07:29 PM
ARNOLD FRANCESDirectorMar 15Sale252.2625063,06510,189Mar 15 07:56 PM
ARNOLD FRANCESDirectorMar 08Sale241.5025060,37510,439Mar 08 07:50 PM
Stapley MarcEVP Strategy & Corp DevelopmtMar 06Sale233.642,000467,28813,787Mar 08 07:45 PM
EASTHAM KARINDirectorMar 05Option Exercise71.092,000142,18015,288Mar 06 07:17 PM
EASTHAM KARINDirectorMar 05Sale229.372,000458,73513,288Mar 06 07:17 PM
Dadswell CharlesSr VP & General CounselMar 05Sale227.1714532,9407,991Mar 06 07:13 PM
OSTADAN OMEADEVP Ops, Products, StrategyMar 02Sale222.661,329295,91628,467Mar 05 09:03 PM
BOWMAN A BLAINEDirectorMar 01Option Exercise44.513,000133,53019,868Mar 05 08:12 PM
BOWMAN A BLAINEDirectorMar 01Sale227.013,000681,02816,868Mar 05 08:12 PM
EPSTEIN ROBERT SDirectorFeb 28Sale231.2525057,8137,088Mar 02 07:06 PM